Denali Therapeutics Inc.

Rinkan Shukla

Mark S Dennis

Adam P Silverman

Yin Sheng Zhang

Xiaocheng Chen

Joy Yu Zuchero

Suresh Poda

Rishi Rakhit

Jennifer A Getz

Do Jin Kim

Lesley Ann Kane

Joseph W Lewcock

In one aspect, antibodies that specifically bind to a human BACE1 protein are provided herein. In some embodiments, the antibodies contain modifications that reduce effector function, extend serum stability or serum half-life, or promote heterodimerization. In other aspects, bispecific antibodies and pharmaceutical compositions comprising antibodies that bind to human BACE1 protein are provided herein. Methods for inhibiting amyloid-&#x3b2; formation and/or aggregation, inhibiting amyloid plaque formation, and treating neurodegenerative diseases are also provided herein.

Anti-BACE1 antibodies and methods of use thereof

In one aspect, antibodies that specifically bind to a human Tau protein are provided. In some embodiments, an anti-Tau antibody recognizes an epitope within residues 111-125 of full-length human Tau, an epitope within residues 251-270 and/or residues 346-360 of full-length human Tau, or an epitope within residues 186-205 of full-length human Tau. In some embodiments, an anti-Tau antibody specifically binds to phosphorylated human Tau, unphosphorylated human Tau, and/or multiple splice isoforms of human Tau. An anti-Tau antibody disclosed herein may also include one or two modified Fc polypeptides.

Anti-Tau antibodies and methods of use thereof

Growing community of inventors

South San Francisco, CA, United States of America

Rinkan Shukla